1
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
2
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
3
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
4
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
5
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
6
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
7
Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism 2011;13:677–84. doi:10.1111/j.1463-1326.2011.01395.x
8
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism 2016;18:203–16. doi:10.1111/dom.12591
9
Ismail-Beigi F. Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine 2012;366:1319–27. doi:10.1056/NEJMcp1013127
10
Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72. doi:10.2337/dc06-9912
11
Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. Medicine 2014;42:711–7. doi:10.1016/j.mpmed.2014.09.011
12
Srinivasan BT, Jarvis J, Khunti K, et al. Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal 2008;84:524–31. doi:10.1136/pgmj.2008.067918
13
Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism 2012;14:780–8. doi:10.1111/j.1463-1326.2012.01580.x
14
June James. Safety and insulin: implementation of national guidance at a local level. Journal of Diabetes Nursinghttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=8&docId=GALE%7CA342482979&docType=Article&sort=RELEVANCE&contentSegment=&prodId=EAIM&contentSet=GALE%7CA342482979&searchId=R6&userGroupName=leicester&inPS=true
15
Rorsman P, Renstr�m E. Insulin granule dynamics in pancreatic beta cells. Diabetologia 2003;46:1029–45. doi:10.1007/s00125-003-1153-1
16
L. Luzi. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology - Endocrinology and Metabolism 1989;257:E241–6.http://ajpendo.physiology.org.ezproxy4.lib.le.ac.uk/content/257/2/E241
17
Luc JC van Loon. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. The American Journal of Clinical Nutrition 2000;72:96–105.http://ajcn.nutrition.org/content/72/1/96.full
18
Menting JG, Whittaker J, Margetts MB, et al. How insulin engages its primary binding site on the insulin receptor. Nature 2013;493:241–5. doi:10.1038/nature11781
19
Wahren J, Kallas A. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? Diabetes 2012;61:2228–9. doi:10.2337/db12-0664
20
Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. 4AD.https://www.youtube.com/watch?v=AhhWTmEFuag
21
Hermansen K, Davies M, Derezinski T, et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care 2006;29:1269–74. doi:10.2337/dc05-1365
22
Richter B, Neises G. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD003816.pub2
23
Holman RR, Turner RC. A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine 1985;2:45–53. doi:10.1111/j.1464-5491.1985.tb00592.x
24
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
25
Crasto W, Jarvis J, Hackett E, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal 2009;85:219–22. doi:10.1136/pgmj.2008.073379
26
Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD006383.pub2
27
Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet 2008;371:1073–84. doi:10.1016/S0140-6736(08)60485-7
28
Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism 2009;11:1153–62. doi:10.1111/j.1463-1326.2009.01154.x
29
Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism 2007;9:630–9. doi:10.1111/j.1463-1326.2006.00654.x
30
Holman RR, Thorne KI, Farmer AJ, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine 2007;357:1716–30. doi:10.1056/NEJMoa075392
31
Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD005613.pub3
32
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html
33
Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489–96. doi:10.2337/dc12-2454
34
Gough SCL, Bhargava A, Jain R, et al. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536–42. doi:10.2337/dc12-2329
35
Hirsch IB, Buse JB, Leahy J, et al. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism 2014;16:206–14. doi:10.1111/dom.12136
36
Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet 2011;377:924–31. doi:10.1016/S0140-6736(10)62305-7
37
Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet 2014;384:2180–1. doi:10.1016/S0140-6736(14)61409-4
38
Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013;36:2945–51. doi:10.2337/dc12-2709
39
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet 2010;375:2234–43. doi:10.1016/S0140-6736(10)60406-0
40
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes. http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/
41
Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD005613.pub3
42
Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine 2011;154. doi:10.7326/0003-4819-154-2-201101180-00300
43
Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care 2014;37:1815–23. doi:10.2337/dc13-3055
44
Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine 2014;31:1293–300. doi:10.1111/dme.12561
45
Hirsch IB, Franek E, Mersebach H, et al. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). Diabetic Medicine 2017;34:167–73. doi:10.1111/dme.13068
46
Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine 2017;34:189–96. doi:10.1111/dme.13256
47
Davies MJ, Leiter LA, Guerci B, et al. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism Published Online First: April 2017. doi:10.1111/dom.12980
48
Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine Published Online First: 2 June 2017. doi:10.1111/dme.13390
49
Daly H, Davies M, Barnett J, et al. Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes 2015;32:305–310a. doi:10.1002/pdi.1979
50
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
51
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html
52
Hannele Yki-Jarvinen,Leena Juurinen,Michael Alvarsson,Tord Bystedt,Ian Caldwell,Melanie Davies. Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Carehttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Clinical+report&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA165017903&contentSet=GALE%7CA165017903
53
Philip Raskin,Elsie Allen,Priscilla Hollander,Andrew Lewin,Robert A. Gabbay,Peter Hu. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Carehttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R5&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA128867472&contentSet=GALE%7CA128867472
54
Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 2008;359:1577–89. doi:10.1056/NEJMoa0806470
55
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine 2012;367:319–28. doi:10.1056/NEJMoa1203858
56
Goudswaard AN, Furlong NJ, Valk GD, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD003418.pub2
57
Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology 2013;1:28–34. doi:10.1016/S2213-8587(13)70006-8
58
Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 2009;361:1736–47. doi:10.1056/NEJMoa0905479
59
Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364–9. doi:10.2337/dc06-1357
60
Davies M, Storms F, Shutler S, et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282–8. doi:10.2337/diacare.28.6.1282
61
Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet 2014;384:2228–34. doi:10.1016/S0140-6736(14)61335-0
62
Yki-Jarvinen H, Kotronen A. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care 2013;36:S205–11. doi:10.2337/dcS13-2026
63
Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990–2000. doi:10.1007/s00125-009-1468-7
64
Wang C, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetic Medicine 2015;32:585–94. doi:10.1111/dme.12694
65
Davies MJ, Chatterjee S. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology 2017;13:317–8. doi:10.1038/nrendo.2017.41
66
Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-11
67
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
68
Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet 2012;379:1489–97. doi:10.1016/S0140-6736(12)60204-9
69
Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes, Obesity and Metabolism 2014;16:922–30. doi:10.1111/dom.12298
70
Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine 2006;23:285–92. doi:10.1111/j.1464-5491.2005.01781.x
71
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 1993;329:977–86. doi:10.1056/NEJM199309303291401
72
Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care 2014;37:9–16. doi:10.2337/dc13-2112
73
Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine 2010;363:311–20. doi:10.1056/NEJMoa1002853
74
Kahler P, Grevstad B, Almdal T, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open 2014;4:e004806–e004806. doi:10.1136/bmjopen-2014-004806
75
Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD009122.pub2
76
Benkhadra K, Alahdab F, Tamhane S, et al. Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. Clinical Endocrinology Published Online First: December 2016. doi:10.1111/cen.13290
77
McCrimmon RJ. Old habits are hard to break: lessons from the study of hypoglycaemia. Diabetic Medicine 2017;34:148–55. doi:10.1111/dme.13277
78
Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine 2004;21:769–75. doi:10.1111/j.1464-5491.2004.01244.x
79
Pickup JC, Reznik Y, Sutton AJ. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care 2017;40:715–22. doi:10.2337/dc16-2201
80
Wang W, Liu H, Xiao S, et al. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy Published Online First: 14 June 2017. doi:10.1007/s13300-017-0282-3
81
Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine 2017;34:1205–11. doi:10.1111/dme.13379
82
Walker RA, Rodgers J, Diabetes UK. Diabetes: a practical guide to managing your health. Fully revised and updated. London: : Dorling Kindersley 2010.
83
Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 2009;361:1736–47. doi:10.1056/NEJMoa0905479
84
Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes, Obesity and Metabolism 2007;9:209–17. doi:10.1111/j.1463-1326.2006.00665.x
85
Anderson JW, Kendall CWC, Jenkins DJA. Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies. Journal of the American College of Nutrition 2003;22:331–9. doi:10.1080/07315724.2003.10719316
86
Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes, Obesity and Metabolism 2007;9:799–812. doi:10.1111/j.1463-1326.2006.00686.x
87
Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002;325:746–746. doi:10.1136/bmj.325.7367.746
88
Anderson B, Funnell M, American Diabetes Association. The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandria, Va: : American Diabetes Association 2005.
89
Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI. http://www.ncbi.nlm.nih.gov/pubmed/17102158
90
Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. Diabetologia Published Online First: 24 December 2016. doi:10.1007/s00125-016-4189-8
91
Peter Mansell. The dose adjustment for normal eating (DAFNE) education programme. Journal of Diabetes Nursinghttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=1&docId=GALE%7CA314268073&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA314268073&searchId=R1&userGroupName=leicester&inPS=true
92 :
Summary of Revisions. Diabetes Care 2016;39:S4–5. doi:10.2337/dc16-S003
93
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008;358:2545–59. doi:10.1056/NEJMoa0802743
94
Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism 2006;8:58–66. doi:10.1111/j.1463-1326.2005.00563.x
95
Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabetic Medicine 2013;30:276–88. doi:10.1111/dme.12019
96
Davies M, Storms F, Shutler S, et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282–8. doi:10.2337/diacare.28.6.1282
97
Park SW, Bebakar WMW, Hernandez PG, et al. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST : SIMPLE USE). Diabetic Medicine 2017;34:174–9. doi:10.1111/dme.13069
98
Matthew C. Riddle,Julio Rosenstock,John Gerich. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Carehttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=9&docId=GALE%7CA110470954&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA110470954&searchId=R3&userGroupName=leicester&inPS=true
99
Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 2012;14:675–88. doi:10.1111/j.1463-1326.2012.01560.x
100
Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine 2014;31:1293–300. doi:10.1111/dme.12561
101
Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 2009;361:1736–47. doi:10.1056/NEJMoa0905479
102
Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care 2014;37:1815–23. doi:10.2337/dc13-3055
103
Bergenstal RM, Johnson M, Powers MA, et al. Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008;31:1305–10. doi:10.2337/dc07-2137
104
Owens DR, Luzio SD, Sert-Langeron C, et al. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes, Obesity and Metabolism 2011;13:1020–7. doi:10.1111/j.1463-1326.2011.01459.x
105
Hannele Yki-Järvinen. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care 2013;36. doi:doi: 10.2337/dcS13-2026
106
Lankisch MR, Ferlinz KC, Leahy JL, et al. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, Obesity and Metabolism Published Online First: September 2008. doi:10.1111/j.1463-1326.2008.00967.x
107
Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990–2000. doi:10.1007/s00125-009-1468-7
108
Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care 2011;34:510–7. doi:10.2337/dc10-1710
109
Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine Published Online First: 2 June 2017. doi:10.1111/dme.13390
110
Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine 2017;34:1193–204. doi:10.1111/dme.13390
111
Martha M. Funnell. Overcoming barriers to the initiation of insulin therapy. Clinical Diabeteshttp://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=8&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA159389875&contentSet=GALE%7CA159389875
112
McBain H, Begum S, Rahman S, et al. Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study. Diabetic Medicine 2017;34:253–61. doi:10.1111/dme.13196
113
Manju Chandran,Steven V. Edelman. Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers). Clinical Diabeteshttp://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=3&docId=GALE%7CA100730300&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA100730300&searchId=R2&userGroupName=leicester&inPS=true
114
Burnett JCD. Long‐ and Short‐Haul Travel by Air: Issues for People With Diabetes on Insulin. Journal of Travel Medicine 2006;13:255–60. doi:10.1111/j.1708-8305.2006.00057.x
115
Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737
116
Hui E, Bravis V, Salih S, et al. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice 2010;64:1095–9. doi:10.1111/j.1742-1241.2010.02347.x
117
Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabetic Medicine 2016;33:1315–29. doi:10.1111/dme.13080
118
Bakiner O, Ertorer ME, Bozkirli E, et al. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetologica 2009;46:63–5. doi:10.1007/s00592-008-0062-7
119
Gregory T. Mucha,Stacia Merkel,William Thomas,John P. Bantle. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Carehttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=17&docId=GALE%7CA116666633&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA116666633&searchId=R8&userGroupName=leicester&inPS=true
120
Diabetes & Metabolism - Présentation - EM consulte. http://www.em-consulte.com/article/80031/alertePM#N1010C
121
Mollema ED, Snoek FJ, Heine RJ, et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetic Medicine 2001;18:671–4. doi:10.1046/j.1464-5491.2001.00547.x
122
Jenkins K. II. Needle phobia: a psychological perspective. British Journal of Anaesthesia 2014;113:4–6. doi:10.1093/bja/aeu013
123
Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice 1999;46:239–46. doi:10.1016/S0168-8227(99)00099-6
124
Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25TM and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Research and Clinical Practice 2003;59:137–43. doi:10.1016/S0168-8227(02)00202-4
125
Akram J, De Verga V, Group the RS. Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. Diabetic Medicine 1999;16:867–74. doi:10.1046/j.1464-5491.1999.00164.x
126
Hui E, Bravis V, Salih S, et al. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice 2010;64:1095–9. doi:10.1111/j.1742-1241.2010.02347.x
127
Simmons JH, McFann KK, Brown AC, et al. Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. Diabetes Care 2007;30:987–8. doi:10.2337/dc06-1553
128
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
129
Lambert K, Holt RIG. The use of insulin analogues in pregnancy. Diabetes, Obesity and Metabolism 2013;15:888–900. doi:10.1111/dom.12098
130
Hyperglycemia and Adverse Pregnancy Outcomes. New England Journal of Medicine 2008;358:1991–2002. doi:10.1056/NEJMoa0707943
131
Gurwitz JH. Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy. Archives of Internal Medicine 1994;154. doi:10.1001/archinte.1994.00420010131015
132
Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931
133
Simmons LR, Molyneaux L, Yue DK, et al. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? ISRN Endocrinology 2012;2012:1–5. doi:10.5402/2012/910905
134
Riddle MC, Rosenstock J, Vlajnic A, et al. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes, Obesity and Metabolism 2014;16:396–402. doi:10.1111/dom.12225
135
June James. End-of-life care: Anything but a pathway. http://www.diabetesandprimarycare.co.uk/media/content/_master/3572/files/pdf/dpc15-6-292-7.pdf
136
Frisch A, Chandra P, Smiley D, et al. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. Diabetes Care 2010;33:1783–8. doi:10.2337/dc10-0304
137
Home P, Riddle M, Cefalu WT, et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–508. doi:10.2337/dc13-2743
138
Jackson MJ, Patvardhan C, Wallace F, et al. Perioperative management of diabetes in elective patients: a region-wide audit. British Journal of Anaesthesia 2016;116:501–6. doi:10.1093/bja/aev554
139
Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. Practical Diabetes International 2011;28:26–7. doi:10.1002/pdi.1547
140
P. Schneiter. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. American Journal of Physiology - Endocrinology and Metabolism 1998;275:E806–13.http://ajpendo.physiology.org/content/275/5/E806
141
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology 2013;9. doi:10.1186/1710-1492-9-30
142
Holman RR, Thorne KI, Farmer AJ, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine 2007;357:1716–30. doi:10.1056/NEJMoa075392
143
Kutz A, Struja T, Hausfater P, et al. The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. Diabetic Medicine Published Online First: February 2017. doi:10.1111/dme.13325
144
Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. Practical Diabetes International 2011;28:26–7. doi:10.1002/pdi.1547
145
Tapley M, Needham E. Improving end of life care for people with diabetes. Practical Diabetes 2012;29:306–307a. doi:10.1002/pdi.1711
146
Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873
147
F Game. Annals of The Royal College of Surgeons of England. 2012;94. doi:doi: 10.1308/003588412X13171221591655
148
Hommel I, van Gurp PJ, Tack CJ, et al. Perioperative diabetes care: room for improving the person centredness. Diabetic Medicine 2015;32:561–8. doi:10.1111/dme.12600
149
Aldam P, Levy N, Hall GM. Perioperative management of diabetic patients: new controversies. British Journal of Anaesthesia 2014;113:906–9. doi:10.1093/bja/aeu259
150
Barker P, Creasey PE, Dhatariya K, et al. Peri-operative management of the surgical patient with diabetes 2015. Anaesthesia 2015;70:1427–40. doi:10.1111/anae.13233
151
Levy N, Penfold N, Mythen M. Perioperative management of diabetes and the emerging role of anaesthetists as perioperative physicians. British Journal of Anaesthesia 2016;116:443–7. doi:10.1093/bja/aew049
152
Bajwa S, Baruah M, Kalra S, et al. Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. Journal of Anaesthesiology Clinical Pharmacology 2015;31. doi:10.4103/0970-9185.155141
153
Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes/Metabolism Research and Reviews 2014;30:96–102. doi:10.1002/dmrr.2486
154
Gururaj Setty S, Crasto W, Jarvis J, et al. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal 2016;92:152–64. doi:10.1136/postgradmedj-2015-133716
155
Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016. https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
156
Bergenstal RM, Rosenstock J, Arakaki RF, et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–7. doi:10.2337/dc12-0060
157
Rosenstock J, Bergenstal RM, Blevins TC, et al. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care 2013;36:522–8. doi:10.2337/dc12-0067
158
Riddle MC, Bolli GB, Ziemen M, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care 2014;37:2755–62. doi:10.2337/dc14-0991
159
Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care 2015;38:2217–25. doi:10.2337/dc15-0249
160
New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086
161
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743
162
Buse JB, Vilsbøll T, Thurman J, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care 2014;37:2926–33. doi:10.2337/dc14-0785
163
EASD Virtual Meeting. http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-sglt2-inhibitors-in-patients-with-type-2-diabetes-mellitus
164
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320
165
Shosuke Satake,Mary Courtney Moore,Kayano Igawa,Margaret Converse,Benjamin Farmer,Doss W. Neal. Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles). Diabeteshttp://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=2&docId=GALE%7CA87347789&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA87347789&searchId=R8&userGroupName=leicester&inPS=true
166
Khedkar A, Iyer H, Anand A, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes, Obesity and Metabolism 2010;12:659–64. doi:10.1111/j.1463-1326.2010.01213.x
167
Luzio SD, Dunseath G, Lockett A, et al. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism 2010;12:82–7. doi:10.1111/j.1463-1326.2009.01146.x
168
W. Blair Geho. A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology 2014;8. doi:doi: 10.1177/1932296814524871
169
Morçöl T, Nagappan P, Nerenbaum L, et al. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. International Journal of Pharmaceutics 2004;277:91–7. doi:10.1016/j.ijpharm.2003.07.015
170
Pozzilli P, Manfrini S, Costanza F, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism 2005;54:930–4. doi:10.1016/j.metabol.2005.02.008
171
Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents. Diabetes Technology & Therapeutics 2004;6:1–8. doi:10.1089/152091504322783341
172
Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. The British Journal of Diabetes & Vascular Disease 2010;10:90–7. doi:10.1177/1474651409355454
173
Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine 2017;34:1193–204. doi:10.1111/dme.13390
174
Lea, Mary R. Creme, Phyllis. Writing At University. 3rd ed. McGraw-Hill Education 2008. http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=345134
175
Bailey S. Academic writing: a handbook for international students. 3rd ed. London: : Routledge 2011. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=310467
